Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 0863 • ACR Convergence 2020
Residual Treatment Burden, Desired Improvement, and Prioritized Treatment Goals in Systemic Lupus Erythematosus (SLE): Results from the SLE-UPDATE (Understanding Preferences, Disease Activity and Treatment Expectations) Survey in the United States
Diane Kamen¹, Julie Birt², Monica Hadi³, Nashmel Sargalo³, Ella Brookes³, Paul Swinburn³, Leslie Hanrahan⁴, Karin Tse⁵, Natalia Bello⁶, Kirstin Griffing², Maria Silk², Laure Delbecque⁷ and Anca Askanase⁸, ¹Medical University of South Carolina, Charleston, SC, ²Eli Lilly and Company, Indianapolis, IN, ³Evidera, London, United Kingdom, ⁴Carra Group, Milwaukee, WI, ⁵Lupus Foundation of America, DC, WA, ⁶Eli Lilly and Company, Indianapolis, ⁷Eli Lilly and Company, Brussels, Belgium, ⁸Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Literature describes a fairly high degree of satisfaction with SLE therapies, despite patients reporting high rates of adverse event (1-2). The objectives of this…
Abstract Number: 0977 • ACR Convergence 2020
Expanded T Peripheral Helper Cells and Increased Pathologic B Cell Lung Infiltration in Pristane-induced Murine Lupus in the Absence of BCL6+ Tfh Cells
Runci Wang¹, Pui Lee², Peter Nigrovic³ and Deepak Rao¹, ¹Brigham and Women's Hospital, Boston, MA, ²1.Boston Children's Hospital;2.Brigham and Women's Hospital;3.Harvard Medical School, Newton, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston
Background/Purpose: PD-1hi CXCR5- T peripheral helper (Tph) cells are highly expanded in RA and SLE patients. Like T follicular helper (Tfh) cells, human Tph cells…
Abstract Number: 1023 • ACR Convergence 2020
Epidemiology and Sociodemographic Distribution of Upper Gastrointestinal Bleeding Among Medicaid Beneficiaries with Systemic Lupus Erythematosus
Chang Xu¹, Molly Perencevich², Seoyoung Kim², Karen Costenbader³ and Candace Feldman¹, ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Individuals with systemic lupus erythematosus (SLE) have multiple risk factors for upper gastrointestinal bleeding (UGIB), including heightened susceptibility to infection and glucocorticoid, NSAID and…
Abstract Number: 1261 • ACR Convergence 2020
Antiphospholipid Patterns Predict the Risk of Thrombosis in Systemic Lupus Erythematosus
Selcan Demir¹, Jessica Li², Laurence Magder³ and Michelle Petri⁴, ¹Hacettepe University Faculty of Medicine, Ankara, Ankara, Turkey, ²Johns Hopkins University, Baltimore, MD, ³University of Maryland, Baltimore, Baltimore, MD, ⁴Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Antiphospholipid syndrome (APS) has been classified as the development of venous and/or arterial thromboses, and/or pregnancy morbidity, in the presence of persistently raised levels…
Abstract Number: 1277 • ACR Convergence 2020
Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus
Pankti Mehta¹, Komal Singh¹, Amita Aggarwal¹ and Seema Sharma¹, ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) are at an increased risk of infection owing to immunosuppressive therapy along with coexistent immune dysregulation. It is…
Abstract Number: 1293 • ACR Convergence 2020
Factors Associated with Early Hospital Readmission in Systemic Lupus Erythematosus: Data from National Readmission Database
Rashmi Dhital¹, Joshua Baker², Paras Karmacharya³, Anthony Donato⁴ and Dilli Poudel², ¹Reading Hospital and Medical Center, West Reading, ²University of Pennsylvania, Philadelphia, PA, ³Mayo Clinic, Rochester MN, ROCHESTER, MN, ⁴Reading Hospital and Medical Center, West Reading, PA
Background/Purpose: Early hospital readmission is a major healthcare burden. Studies evaluating factors associated with readmissions in rheumatic diseases are sparse. Our aim was to use…
Abstract Number: 1474 • ACR Convergence 2020
Early Peak of Cardiovascular Events Occurs Equally in Caucasians and African-American SLE but Is Attributed to Different Risk Factors
Michelle Petri¹, Jessica Li² and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Timonium, MD, ²Johns Hopkins University, Baltimore, MD
Background/Purpose: The classic bimodal pattern of morbidity/mortality in SLE highlighted that cardiovascular events occurred later in the natural history of SLE (Urowitz & Gladman. J…
Abstract Number: 1593 • ACR Convergence 2020
Adherence to Weight-Based Dosing Guidelines in Patients Receiving Hydroxychloroquine for Rheumatoid Arthritis and Systemic Lupus Erythematosus: Results of a Quality Improvement Initiative
Tara Skorupa¹ and Robert Shmerling², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²Beth Israel Deaconess Medical Center/Harvard Medical School, Division of Rheumatology, Mashpee, MA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly prescribed medication for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and other rheumatic diseases. HCQ may rarely cause retinopathy.…
Abstract Number: 1678 • ACR Convergence 2020
Hydroxychloroquine Blood Levels Predicts 6-Months Disease Activity in Juvenile Lupus Nephritis
Verena Balbi¹, Clovis Silva², Tatiana Pedrosa³, Rosa Pereira³, Lucia Campos³, Elaine Leon³, Nilo Duarte³, Valdemir Carvalho⁴, Sandra Pasoto³, Debora Rosario³, Leticia Brandao³, Eloisa Bonfa³ and Nadia Aikawa³, ¹Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao paulo, Brazil, ²Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ³Hospital das Clínicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Sao Paulo, Brazil, ⁴Fleury Group, Sao Paulo, Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Renal involvement is reported in up to 80% of juvenile systemic lupus erithematosus (JSLE) and its among the most severe manifestations in these population. Antimalarials are one of…
Abstract Number: 1790 • ACR Convergence 2020
Association of Telomere Length and the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) in Long Standing Systemic Lupus Erythematosus
Kaitlin Lima¹, Alexandra Legge², John Hanly², Jungwha Lee³, Jing Song³, Anh Chung³, Carly Skamra⁴, QiQuan Huang¹, Richard Pope⁵ and Rosalind Ramsey-Goldman⁶, ¹Northwestern University, Chicago, IL, ²Dalhousie University, Halifax, NS, Canada, ³Northwestern University, Chicago, ⁴Northwestern University, Brookfield, IL, ⁵McGaw Medical Center of Northwestern University, Chicago, IL, ⁶Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Frailty, an emerging concept in SLE, represents an individual’s ability to respond to physiologic stress. The first lupus-specific frailty index, the SLICC-FI, was recently…
Abstract Number: 1808 • ACR Convergence 2020
Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d (EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia in Pregnant Women with Systemic Lupus Erythematosus (SLE)
Jill Buyon¹, John Conklin², Michael Golpanian¹, JoAnne Ligayon³, Thierry Dervieux⁴, Peter Izmirly¹, H. Michael Belmont¹, Jane Salmon⁵ and Roberta Vezza Alexander³, ¹New York University, New York, NY, ²Exagen Inc., Vista, CA, ³Exagen Inc, Vista, CA, ⁴Exagen Inc, San Diego, CA, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Despite improvement in management and outcomes of pregnancies complicated by SLE, the risk of adverse events and preeclampsia (PE) continues to exceed that of…
Abstract Number: 1825 • ACR Convergence 2020
Risk Factors for Antimalarial-Induced Retinal Toxicity in Systemic Lupus Erythematosus and Other Rheumatic Diseases
Gemma Cramarossa¹, Hsin-Yen Liu² and Janet Pope³, ¹Western University, Kleinburg, ON, Canada, ²Western University, London, ON, Canada, ³Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada
Background/Purpose: Hydroxychloroquine (HCQ) and chloroquine (CQ) are antimalarial (AM) medications prescribed for a variety of rheumatic diseases, including systemic lupus erythematosus (SLE). Many patients will…
Abstract Number: 1842 • ACR Convergence 2020
Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus: Post Hoc Analyses of Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-blind, Placebo-Controlled Trial
Anca Askanase¹, George Wan², Mary Panaccio², Enxu Zhao², Julie Zhu², Roman Bilyk² and Richard Furie³, ¹Columbia University College of Physicians and Surgeons, New York, NY, ²Mallinckrodt Pharmaceuticals, Bedminster, NJ, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY
Background/Purpose: Repository corticotropin injection (RCI, Mallinckrodt Pharmaceuticals) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides approved for the treatment…
Abstract Number: 0246 • ACR Convergence 2020
Extreme Fatigue in Patients with Systemic Lupus Erythematosus and Neuropsychiatric Symptoms
Rory Monahan¹, Rolf Fronczek¹, Jeroen Eikenboom¹, Huub Middelkoop¹, Liesbeth Beaart-van de Voorde¹, Gisela Terwindt¹, Nic van der Wee¹, Thomas Huizinga¹, Margreet Kloppenburg¹ and Margreet Steup-Beekman¹, ¹Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Fatigue is commonly described in chronic illnesses, especially in auto-immune disorders such as systemic lupus erythematosus (SLE). We aim to study the prevalence of…
Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].